Results 21 to 30 of about 700,247 (353)
Respiratory Research, 2018 Background The objective of this study was to assess, whether right atrial (RA) and ventricular (RV) size is related to RV pump function at rest and during exercise in patients with pulmonary arterial hypertension (PAH).
Lukas Fischer +12 more
doaj +1 more source
Life, 2023 Advances in the diagnosis and treatment of pulmonary hypertension (PH) have gradually improved the disease course. This retrospective cohort study aims to explore the diagnostic hemodynamic profile and survival of PH patients and their temporal changes ...
Georgios E. Papadopoulos +12 more
doaj +1 more source
Micro-RNA-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 1 [PDF]
, 2018 Sphingosine kinase 1 (SphK1) upregulation is associated with pathologic pulmonary vascular remodeling in pulmonary arterial hypertension (PAH), but the mechanisms controlling its expression are undefined.
Chen, Jiwang +6 more
core +1 more source
MicroRNA-483 amelioration of experimental pulmonary hypertension. [PDF]
, 2020 Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit.
Bai, Liang +22 more
core +1 more source
BMC Pulmonary Medicine, 2017 Background Chronic inflammation emerges as a feature of the pathogenesis of pulmonary arterial hypertension (PAH) in experimental models. Alterations of circulating cell subsets have been observed in patients with PAH.
Lars Harbaum +9 more
doaj +1 more source
MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase [PDF]
, 2019 Nicotinamide phosphoribosyltransferase (NAMPT) upregulation in human pulmonary artery endothelial cells (hPAECs) is associated with pulmonary arterial hypertension (PAH) progression and pulmonary vascular remodeling.
Chen, Jiwang +7 more
core +1 more source
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. [PDF]
, 2013 BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3,
CHEST-1 Study Group, +13 more
core +1 more source
Current Problems in Cardiology, 2004 Pulmonary hypertension, in its simplest sense, is elevation of the pulmonary artery pressure above normal. A multitude of diseases may increase the pulmonary artery pressure and result in right ventricular dysfunction. The treatments of pulmonary hypertension are as varied as its causes.
Vallerie V, McLaughlin, Stuart, Rich
openaire +2 more sources
Metformin reverses development of pulmonary hypertension via aromatase inhibition [PDF]
, 2016 Females are more susceptible to pulmonary arterial hypertension than males, although the reasons remain unclear. The hypoglycemic drug, metformin, is reported to have multiple actions, including the inhibition of aromatase and stimulation of AMP ...
Dean, Afshan +4 more
core +2 more sources
Reversal of Pulmonary Hypertension in a Patient with Chronic Mountain Sickness after Relocation to Low Altitude [PDF]
Journal of Clinical and Diagnostic Research, 2021 Long-term high altitude residence can be complicated by development of Chronic Mountain Sickness (CMS) characterised by excessive erythrocytosis and neurological symptoms.
Abdirashit Maripov +4 more
doaj +1 more source